NR1H4 and metabolic dysfunction-associated steatohepatitis: As consequence of abnormal levels in bile acid concentrations that associate with liver fibrosis and inflammation (Fiorucci and Baldelli, 2009; Fiorucci et al., 2010; Fiorucci et al., 2014; Sepe et al., 2015), FXR has been identified as an appealing target for the treatment of primary biliary cirrhosis (PBC), NAFLD, and NASH (Fiorucci and Baldelli, 2009; Fiorucci et al., 2011; Fiorucci et al., 2012a; Fiorucci et al., 2012b).